Oncobiologics Warrants Series A Exp 18 Feb 2019 (ONSIW) SWOT Analysis / TOWS Matrix / MBA Resources
Strategy / MBA Resources
Introduction to SWOT Analysis
SWOT Analysis / TOWS Matrix for Oncobiologics Warrants Series A Exp 18 Feb 2019 (United States)
Based on various researches at Oak Spring University , Oncobiologics Warrants Series A Exp 18 Feb 2019 is operating in a macro-environment that has been destablized by – technology disruption, cloud computing is disrupting traditional business models, central banks are concerned over increasing inflation, there is backlash against globalization, supply chains are disrupted by pandemic , increasing commodity prices, competitive advantages are harder to sustain because of technology dispersion,
wage bills are increasing, increasing household debt because of falling income levels, etc
Introduction to SWOT Analysis of Oncobiologics Warrants Series A Exp 18 Feb 2019
SWOT stands for an organization’s Strengths, Weaknesses, Opportunities and Threats . At Oak Spring University, we believe that Oncobiologics Warrants Series A Exp 18 Feb 2019 can use SWOT analysis as a strategic management tool to assess the current internal strengths and weaknesses of the Oncobiologics Warrants Series A Exp 18 Feb 2019, and to figure out the opportunities and threats in the macro environment – technological, environmental, political, economic, social, demographic, etc in which Oncobiologics Warrants Series A Exp 18 Feb 2019 operates in.
According to Harvard Business Review, 75% of the managers use SWOT analysis for various purposes such as – evaluating current scenario, strategic planning, new venture feasibility, personal growth goals, new market entry, Go To market strategies, portfolio management and strategic trade-off assessment, organizational restructuring, etc.
SWOT Objectives / Importance of SWOT Analysis and SWOT Matrix
SWOT analysis of Oncobiologics Warrants Series A Exp 18 Feb 2019 can be done for the following purposes –
1. Strategic planning of Oncobiologics Warrants Series A Exp 18 Feb 2019
2. Improving business portfolio management of Oncobiologics Warrants Series A Exp 18 Feb 2019
3. Assessing feasibility of the new initiative in United States
4. Making a sector specific business decision
5. Set goals for the organization
6. Organizational restructuring of Oncobiologics Warrants Series A Exp 18 Feb 2019
Strengths of Oncobiologics Warrants Series A Exp 18 Feb 2019 | Internal Strategic Factors
What are Strengths in SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
The strengths of Oncobiologics Warrants Series A Exp 18 Feb 2019 are -
Highly skilled collaborators
– Oncobiologics Warrants Series A Exp 18 Feb 2019 has highly efficient outsourcing and offshoring strategy. It has resulted in greater operational flexibility and bringing down the costs in highly price sensitive industry. Secondly the value chain collaborators of Oncobiologics Warrants Series A Exp 18 Feb 2019 have helped the firm to develop new products and bring them quickly to the marketplace.
Organizational Resilience of Oncobiologics Warrants Series A Exp 18 Feb 2019
– The covid-19 pandemic has put organizational resilience at the centre of everthing Oncobiologics Warrants Series A Exp 18 Feb 2019 does. Organizational resilience comprises - Financial Resilience, Operational Resilience, Technological Resilience, Organizational Resilience, Business Model Resilience, and Reputation Resilience.
Learning organization
- Oncobiologics Warrants Series A Exp 18 Feb 2019 is a learning organization. It has inculcated three key characters of learning organization in its processes and operations – exploration, creativity, and expansiveness. The work place at Oncobiologics Warrants Series A Exp 18 Feb 2019 is open place that encourages instructiveness, ideation, open minded discussions, and creativity. Employees and leaders at Oncobiologics Warrants Series A Exp 18 Feb 2019 emphasize – knowledge, initiative, and innovation.
Digital Transformation in industry
- digital transformation varies from industry to industry. For Oncobiologics Warrants Series A Exp 18 Feb 2019 digital transformation journey comprises differing goals based on market maturity, customer technology acceptance, and organizational culture. Oncobiologics Warrants Series A Exp 18 Feb 2019 has successfully integrated the four key components of digital transformation – digital integration in processes, digital integration in marketing and customer relationship management, digital integration into the value chain, and using technology to explore new products and market opportunities.
Ability to recruit top talent
– Oncobiologics Warrants Series A Exp 18 Feb 2019 is one of the leading players in the industry in United States. It is in a position to attract the best talent available in United States. The firm has a robust talent identification program that helps in identifying the brightest.
Successful track record of launching new products
– Oncobiologics Warrants Series A Exp 18 Feb 2019 has launched numerous new products in last few years, keeping in mind evolving customer preferences and competitive pressures. Oncobiologics Warrants Series A Exp 18 Feb 2019 has effective processes in place that helps in exploring new product needs, doing quick pilot testing, and then launching the products quickly using its extensive distribution network.
Diverse revenue streams
– Oncobiologics Warrants Series A Exp 18 Feb 2019 is present in almost all the verticals within the industry. This has provided Oncobiologics Warrants Series A Exp 18 Feb 2019 a diverse revenue stream that has helped it to survive disruptions such as global pandemic in Covid-19, financial disruption of 2008, and supply chain disruption of 2021.
High switching costs
– The high switching costs that Oncobiologics Warrants Series A Exp 18 Feb 2019 has built up over years in its products and services combo offer has resulted in high retention of customers, lower marketing costs, and greater ability of the firm to focus on its customers.
Training and development
– Oncobiologics Warrants Series A Exp 18 Feb 2019 has one of the best training and development program in industry. The effectiveness of the training programs can be measured in – employees retention, in-house promotion, loyalty, new venture initiation, lack of conflict, and high level of both employees and customer engagement.
Sustainable margins compare to other players in industry
– Oncobiologics Warrants Series A Exp 18 Feb 2019 has clearly differentiated products in the market place. This has enabled Oncobiologics Warrants Series A Exp 18 Feb 2019 to fetch slight price premium compare to the competitors in the industry. The sustainable margins have also helped Oncobiologics Warrants Series A Exp 18 Feb 2019 to invest into research and development (R&D) and innovation.
High brand equity
– Oncobiologics Warrants Series A Exp 18 Feb 2019 has strong brand awareness and brand recognition among both - the exiting customers and potential new customers. Strong brand equity has enabled Oncobiologics Warrants Series A Exp 18 Feb 2019 to keep acquiring new customers and building profitable relationship with both the new and loyal customers.
Operational resilience
– The operational resilience strategy of Oncobiologics Warrants Series A Exp 18 Feb 2019 comprises – understanding the underlying the factors in the industry, building diversified operations across different geographies so that disruption in one part of the world doesn’t impact the overall performance of the firm, and integrating the various business operations and processes through its digital transformation drive.
Weaknesses of Oncobiologics Warrants Series A Exp 18 Feb 2019 | Internal Strategic Factors
What are Weaknesses in SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
The weaknesses of Oncobiologics Warrants Series A Exp 18 Feb 2019 are -
No frontier risks strategy
– From the 10K / annual statement of Oncobiologics Warrants Series A Exp 18 Feb 2019, it seems that company is thinking out the frontier risks that can impact industry. But it has very little resources allocation to manage the risks emerging from events such as natural disasters, climate change, melting of permafrost, tacking the rise of artificial intelligence, opportunities and threats emerging from commercialization of space etc.
High operating costs
– Compare to the competitors, Oncobiologics Warrants Series A Exp 18 Feb 2019 has high operating costs in the industry. This can be harder to sustain given the new emerging competition from nimble players who are using technology to attract Oncobiologics Warrants Series A Exp 18 Feb 2019 lucrative customers.
Need for greater diversity
– Oncobiologics Warrants Series A Exp 18 Feb 2019 has taken concrete steps on diversity, equity, and inclusion. But the efforts so far has resulted in limited success. It needs to expand the recruitment and selection process to hire more people from the minorities and underprivileged background.
Slow to harness new channels of communication
– Even though competitors are using new communication channels such as Instagram, Tiktok, and Snap, Oncobiologics Warrants Series A Exp 18 Feb 2019 is slow explore the new channels of communication. These new channels of communication can help Oncobiologics Warrants Series A Exp 18 Feb 2019 to provide better information regarding products and services. It can also build an online community to further reach out to potential customers.
High cash cycle compare to competitors
Oncobiologics Warrants Series A Exp 18 Feb 2019 has a high cash cycle compare to other players in the industry. It needs to shorten the cash cycle by 12% to be more competitive in the marketplace, reduce inventory costs, and be more profitable.
High dependence on existing supply chain
– The disruption in the global supply chains because of the Covid-19 pandemic and blockage of the Suez Canal illustrated the fragile nature of Oncobiologics Warrants Series A Exp 18 Feb 2019 supply chain. Even after few cautionary changes, Oncobiologics Warrants Series A Exp 18 Feb 2019 is still heavily dependent upon the existing supply chain. The existing supply chain though brings in cost efficiencies but it has left Oncobiologics Warrants Series A Exp 18 Feb 2019 vulnerable to further global disruptions in South East Asia.
Lack of clear differentiation of Oncobiologics Warrants Series A Exp 18 Feb 2019 products
– To increase the profitability and margins on the products, Oncobiologics Warrants Series A Exp 18 Feb 2019 needs to provide more differentiated products than what it is currently offering in the marketplace.
Increasing silos among functional specialists
– The organizational structure of Oncobiologics Warrants Series A Exp 18 Feb 2019 is dominated by functional specialists. It is not different from other players in the industry, but Oncobiologics Warrants Series A Exp 18 Feb 2019 needs to de-silo the office environment to harness the true potential of its workforce. Secondly the de-silo will also help Oncobiologics Warrants Series A Exp 18 Feb 2019 to focus more on services in the industry rather than just following the product oriented approach.
Employees’ less understanding of Oncobiologics Warrants Series A Exp 18 Feb 2019 strategy
– From the outside it seems that the employees of Oncobiologics Warrants Series A Exp 18 Feb 2019 don’t have comprehensive understanding of the firm’s strategy. This is reflected in number of promotional campaigns over the last few years that had mixed messaging and competing priorities. Some of the strategic activities and services promoted in the promotional campaigns were not consistent with the organization’s strategy.
Slow to strategic competitive environment developments
– As Oncobiologics Warrants Series A Exp 18 Feb 2019 is one of the leading players in the industry, it takes time to assess the upcoming competitions. This has led to missing out on atleast 2-3 big opportunities in the industry in last five years.
Skills based hiring in industry
– The stress on hiring functional specialists at Oncobiologics Warrants Series A Exp 18 Feb 2019 has created an environment where the organization is dominated by functional specialists rather than management generalist. This has resulted into product oriented approach rather than marketing oriented approach or consumers oriented approach.
Oncobiologics Warrants Series A Exp 18 Feb 2019 Opportunities | External Strategic Factors
What are Opportunities in the SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
The opportunities of Oncobiologics Warrants Series A Exp 18 Feb 2019 are -
Building a culture of innovation
– managers at Oncobiologics Warrants Series A Exp 18 Feb 2019 can make experimentation a productive activity and build a culture of innovation using approaches such as – mining transaction data, A/B testing of websites and selling platforms, engaging potential customers over various needs, and building on small ideas in the industry.
Redefining models of collaboration and team work
– As explained in the weaknesses section, Oncobiologics Warrants Series A Exp 18 Feb 2019 is facing challenges because of the dominance of functional experts in the organization. Oncobiologics Warrants Series A Exp 18 Feb 2019 can utilize new technology in the field of industry to build more coordinated teams and streamline operations and communications using tools such as CAD, Zoom, etc.
Creating value in data economy
– The success of analytics program of Oncobiologics Warrants Series A Exp 18 Feb 2019 has opened avenues for new revenue streams for the organization in industry. This can help Oncobiologics Warrants Series A Exp 18 Feb 2019 to build a more holistic ecosystem for Oncobiologics Warrants Series A Exp 18 Feb 2019 products in the industry by providing – data insight services, data privacy related products, data based consulting services, etc.
Leveraging digital technologies
– Oncobiologics Warrants Series A Exp 18 Feb 2019 can leverage digital technologies such as artificial intelligence and machine learning to automate the production process, customer analytics to get better insights into consumer behavior, realtime digital dashboards to get better sales tracking, logistics and transportation, product tracking, etc.
Manufacturing automation
– Oncobiologics Warrants Series A Exp 18 Feb 2019 can use the latest technology developments to improve its manufacturing and designing process in sector. It can use CAD and 3D printing to build a quick prototype and pilot testing products. It can leverage automation using machine learning and artificial intelligence to do faster production at lowers costs, and it can leverage the growth in satellite and tracking technologies to improve inventory management, transportation, and shipping.
Developing new processes and practices
– Oncobiologics Warrants Series A Exp 18 Feb 2019 can develop new processes and procedures in industry using technology such as automation using artificial intelligence, real time transportation and products tracking, 3D modeling for concept development and new products pilot testing etc.
Reconfiguring business model
– The expansion of digital payment system, the bringing down of international transactions costs using Bitcoin and other blockchain based currencies, etc can help Oncobiologics Warrants Series A Exp 18 Feb 2019 to reconfigure its entire business model. For example it can used blockchain based technologies to reduce piracy of its products in the big markets such as China. Secondly it can use the popularity of e-commerce in various developing markets to build a Direct to Customer business model rather than the current Channel Heavy distribution network.
Better consumer reach
– The expansion of the 5G network will help Oncobiologics Warrants Series A Exp 18 Feb 2019 to increase its market reach. Oncobiologics Warrants Series A Exp 18 Feb 2019 will be able to reach out to new customers. Secondly 5G will also provide technology framework to build new tools and products that can help more immersive consumer experience and faster consumer journey.
Identify volunteer opportunities
– Covid-19 has impacted working population in two ways – it has led to people soul searching about their professional choices, resulting in mass resignation. Secondly it has encouraged people to do things that they are passionate about. This has opened opportunities for businesses to build volunteer oriented socially driven projects. Oncobiologics Warrants Series A Exp 18 Feb 2019 can explore opportunities that can attract volunteers and are consistent with its mission and vision.
Use of Bitcoin and other crypto currencies for transactions in industry
– The popularity of Bitcoin and other crypto currencies as asset class and medium of transaction has opened new opportunities for Oncobiologics Warrants Series A Exp 18 Feb 2019 in the industry. Now Oncobiologics Warrants Series A Exp 18 Feb 2019 can target international markets with far fewer capital restrictions requirements than the existing system.
Lowering marketing communication costs
– 5G expansion will open new opportunities for Oncobiologics Warrants Series A Exp 18 Feb 2019 in the field of marketing communication. It will bring down the cost of doing business, provide technology platform to build new products in the industry, and it will provide faster access to the consumers.
Changes in consumer behavior post Covid-19
– consumer behavior has changed in the industry because of Covid-19 restrictions. Some of this behavior will stay once things get back to normal. Oncobiologics Warrants Series A Exp 18 Feb 2019 can take advantage of these changes in consumer behavior to build a far more efficient business model. For example consumer regular ordering of products can reduce both last mile delivery costs and market penetration costs. Oncobiologics Warrants Series A Exp 18 Feb 2019 can further use this consumer data to build better customer loyalty, provide better products and service collection, and improve the value proposition in inflationary times.
Using analytics as competitive advantage
– Oncobiologics Warrants Series A Exp 18 Feb 2019 has spent a significant amount of money and effort to integrate analytics and machine learning into its operations in sector. This continuous investment in analytics has enabled Oncobiologics Warrants Series A Exp 18 Feb 2019 to build a competitive advantage using analytics. The analytics driven competitive advantage can help Oncobiologics Warrants Series A Exp 18 Feb 2019 to build faster Go To Market strategies, better consumer insights, developing relevant product features, and building a highly efficient supply chain.
Threats Oncobiologics Warrants Series A Exp 18 Feb 2019 External Strategic Factors
What are Threats in the SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
The threats of Oncobiologics Warrants Series A Exp 18 Feb 2019 are -
Barriers of entry lowering
– As technology is more democratized, the barriers to entry to industry are lowering. It can presents Oncobiologics Warrants Series A Exp 18 Feb 2019 with greater competitive threats in the near to medium future. Secondly it will also put downward pressure on pricing throughout the sector.
Aging population
– As the populations of most advanced economies are aging, it will lead to high social security costs, higher savings among population, and lower demand for goods and services in the economy. The household savings in US, France, UK, Germany, and Japan are growing faster than predicted because of uncertainty caused by pandemic.
Technology acceleration in Forth Industrial Revolution
– Oncobiologics Warrants Series A Exp 18 Feb 2019 has witnessed rapid integration of technology during Covid-19 in the industry. As one of the leading players in the industry, Oncobiologics Warrants Series A Exp 18 Feb 2019 needs to keep up with the evolution of technology in the sector. According to Mckinsey study top managers believe that the adoption of technology in operations, communications is 20-25 times faster than what they planned in the beginning of 2019.
New competition
– After the dotcom bust of 2001, financial crisis of 2008-09, the business formation in US economy had declined. But in 2020 alone, there are more than 1.5 million new business applications in United States. This can lead to greater competition for Oncobiologics Warrants Series A Exp 18 Feb 2019 in the sector and impact the bottomline of the organization.
Instability in the European markets
– European Union markets are facing three big challenges post Covid – expanded balance sheets, Brexit related business disruption, and aggressive Russia looking to distract the existing security mechanism. Oncobiologics Warrants Series A Exp 18 Feb 2019 will face different problems in different parts of Europe. For example it will face inflationary pressures in UK, France, and Germany, balance sheet expansion and demand challenges in Southern European countries, and geopolitical instability in the Eastern Europe.
Consumer confidence and its impact on Oncobiologics Warrants Series A Exp 18 Feb 2019 demand
– There is a high probability of declining consumer confidence, given – high inflammation rate, rise of gig economy, lower job stability, increasing cost of living, higher interest rates, and aging demography. All the factors contribute to people saving higher rate of their income, resulting in lower consumer demand in industry and other sectors.
Shortening product life cycle
– it is one of the major threat that Oncobiologics Warrants Series A Exp 18 Feb 2019 is facing in sector. It can lead to higher research and development costs, higher marketing expenses, lower customer loyalty, etc.
Capital market disruption
– During the Covid-19, Dow Jones has touched record high. The valuations of a number of companies are way beyond their existing business model potential. This can lead to capital market correction which can put a number of suppliers, collaborators, value chain partners in great financial difficulty. It will directly impact the business of Oncobiologics Warrants Series A Exp 18 Feb 2019.
High level of anxiety and lack of motivation
– the Great Resignation in United States is the sign of broader dissatisfaction among the workforce in United States. Oncobiologics Warrants Series A Exp 18 Feb 2019 needs to understand the core reasons impacting the industry. This will help it in building a better workplace.
Easy access to finance
– Easy access to finance in industry will also reduce the barriers to entry in the industry, thus putting downward pressure on the prices because of increasing competition. Oncobiologics Warrants Series A Exp 18 Feb 2019 can utilize it by borrowing at lower rates and invest it into research and development, capital expenditure to fortify its core competitive advantage.
Regulatory challenges
– Oncobiologics Warrants Series A Exp 18 Feb 2019 needs to prepare for regulatory challenges as consumer protection groups and other pressure groups are vigorously advocating for more regulations on big business - to reduce inequality, to create a level playing field, to product data privacy and consumer privacy, to reduce the influence of big money on democratic institutions, etc. This can lead to significant changes in the industry regulations.
Stagnating economy with rate increase
– Oncobiologics Warrants Series A Exp 18 Feb 2019 can face lack of demand in the market place because of Fed actions to reduce inflation. This can lead to sluggish growth in the economy, lower demands, lower investments, higher borrowing costs, and consolidation in the industry.
Environmental challenges
– Oncobiologics Warrants Series A Exp 18 Feb 2019 needs to have a robust strategy against the disruptions arising from climate change and energy requirements. EU has identified it as key priority area and spending 30% of its 880 billion Euros European post Covid-19 recovery funds on green technology. Oncobiologics Warrants Series A Exp 18 Feb 2019 can take advantage of this fund but it will also bring new competitors in the industry.
Weighted SWOT Analysis of Oncobiologics Warrants Series A Exp 18 Feb 2019 Template, Example
Not all factors mentioned under the Strengths, Weakness, Opportunities, and Threats quadrants in the SWOT Analysis are equal. Managers at Oncobiologics Warrants Series A Exp 18 Feb 2019 needs to zero down on the relative importance of each factor mentioned in the Strengths, Weakness, Opportunities, and Threats quadrants.
We can provide the relative importance to each factor by assigning relative weights. Weighted SWOT analysis process is a three stage process –
First stage for doing weighted SWOT analysis of Oncobiologics Warrants Series A Exp 18 Feb 2019 is to rank the strengths and weaknesses of the organization. This will help you to assess the most important strengths and weaknesses of the firm and which one of the strengths and weaknesses mentioned in the initial lists are marginal and can be left out.
Second stage for conducting weighted SWOT analysis of Oncobiologics Warrants Series A Exp 18 Feb 2019 is to give probabilities to the external strategic factors thus better understanding the opportunities and threats arising out of macro environment changes and developments.
Third stage of constructing weighted SWOT analysis of Oncobiologics Warrants Series A Exp 18 Feb 2019 to provide strategic recommendations includes – joining likelihood of external strategic factors such as opportunities and threats to the internal strategic factors – strengths and weaknesses. You should start with external factors as they will provide the direction of the overall industry. Secondly by joining probabilities with internal strategic factors can help the company not only strategic fit but also the most probably strategic trade-off that Oncobiologics Warrants Series A Exp 18 Feb 2019 needs to make to build a sustainable competitive advantage.